BR112012004697A2 - purificação melhorada de proteína através de uma eluição da proteína a modificada. - Google Patents

purificação melhorada de proteína através de uma eluição da proteína a modificada.

Info

Publication number
BR112012004697A2
BR112012004697A2 BR112012004697A BR112012004697A BR112012004697A2 BR 112012004697 A2 BR112012004697 A2 BR 112012004697A2 BR 112012004697 A BR112012004697 A BR 112012004697A BR 112012004697 A BR112012004697 A BR 112012004697A BR 112012004697 A2 BR112012004697 A2 BR 112012004697A2
Authority
BR
Brazil
Prior art keywords
protein
elution
modified
enhanced
purification
Prior art date
Application number
BR112012004697A
Other languages
English (en)
Other versions
BR112012004697B8 (pt
BR112012004697B1 (pt
Inventor
Arick Brown
Asha Nandini Radhamohan
Christopher J Dowd
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43649614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012004697(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR112012004697A2 publication Critical patent/BR112012004697A2/pt
Publication of BR112012004697B1 publication Critical patent/BR112012004697B1/pt
Publication of BR112012004697B8 publication Critical patent/BR112012004697B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

a presente invenção refere-se a métodos para purificação de um polipeptídeo que compreende uma região c~ h~2/c~ h~3, compreendendo a ligação do polipeptídeo à proteína a e eluição com um grandiente de ph que começa em um ph baixo.
BR112012004697A 2009-09-01 2010-09-01 método para purificar um polipeptídeo compreendendo uma região ch2/ch3 BR112012004697B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23886709P 2009-09-01 2009-09-01
US61/238,867 2009-09-01
US25343809P 2009-10-20 2009-10-20
US61/253,438 2009-10-20
PCT/US2010/047448 WO2011028753A1 (en) 2009-09-01 2010-09-01 Enhanced protein purification through a modified protein a elution

Publications (3)

Publication Number Publication Date
BR112012004697A2 true BR112012004697A2 (pt) 2015-09-08
BR112012004697B1 BR112012004697B1 (pt) 2021-02-09
BR112012004697B8 BR112012004697B8 (pt) 2021-05-25

Family

ID=43649614

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012004697A BR112012004697B8 (pt) 2009-09-01 2010-09-01 método para purificar um polipeptídeo compreendendo uma região ch2/ch3

Country Status (14)

Country Link
US (3) US9428548B2 (pt)
EP (2) EP2473617B1 (pt)
JP (1) JP5787891B2 (pt)
KR (1) KR101764449B1 (pt)
CN (2) CN102686738A (pt)
BR (1) BR112012004697B8 (pt)
CA (1) CA2772653C (pt)
ES (1) ES2787234T3 (pt)
HR (1) HRP20200581T1 (pt)
MX (1) MX2012002565A (pt)
PL (1) PL2473617T3 (pt)
RU (1) RU2571929C2 (pt)
SI (1) SI2473617T1 (pt)
WO (1) WO2011028753A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
WO2008033517A2 (en) 2006-09-13 2008-03-20 Abbott Laboratories Cell culture improvements
CN104974251A (zh) 2008-10-20 2015-10-14 Abbvie公司 在抗体纯化过程中的病毒灭活
EP2921501A1 (en) 2008-10-20 2015-09-23 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
MX346115B (es) 2009-08-06 2017-03-08 Genentech Inc * Metodo para mejorar la eliminación de virus en la purificacion proteica.
MX2012002901A (es) * 2009-09-10 2012-06-27 Lonza Biologics Plc Metodo y sistema para purificacion de polipeptidos.
BR112014015101A8 (pt) * 2011-12-22 2021-06-08 Genentech Inc métodos para intensificar eficiência de etapas de cromatografia a jusante para purificação de anticorpos
JP6420756B2 (ja) 2012-03-28 2018-11-07 ジーイー・ヘルスケア・バイオプロセス・アールアンドディ・アクチボラグ アフィニティークロマトグラフィーマトリックス
ES2895173T3 (es) 2012-06-29 2022-02-17 Emd Millipore Corp Métodos para inactivar virus durante un proceso de purificación de proteínas
US8921113B2 (en) 2012-12-21 2014-12-30 Dionex Corporation Buffer kit and method of generating a linear pH gradient
KR101838039B1 (ko) * 2013-03-14 2018-03-14 이엠디 밀리포어 코포레이션 단백질 a 기반 크로마토그래피를 이용한 단백질 순도의 증가 방법
KR102251127B1 (ko) * 2013-07-12 2021-05-11 제넨테크, 인크. 이온 교환 크로마토그래피 입력 최적화의 설명
CA2930687C (en) * 2013-11-15 2024-04-23 Genentech, Inc. Methods for viral inactivation using eco-friendly detergents
HUE048782T2 (hu) * 2014-03-10 2020-08-28 Richter Gedeon Nyrt Immunoglobulin tisztítása elõtisztítási lépések alkalmazásával
GB2539420B (en) * 2015-06-16 2021-01-13 Cytiva Sweden Ab Determination of chromatography conditions
TW202016151A (zh) 2018-06-09 2020-05-01 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
US11022585B2 (en) 2019-06-09 2021-06-01 Dionex Corporation Methods and systems for optimizing buffer conditions with liquid chromatography

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP2755395B2 (ja) 1987-09-23 1998-05-20 ブリストル―マイアーズ スクイブ コムパニー Ｈｉｖ感染細胞に殺作用する抗体異種結合体
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
EP0420937B1 (en) 1988-06-21 1994-11-09 Genentech, Inc. Therapeutic compositions for the treatment of myocardial infarction
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DK0479909T3 (da) 1989-06-29 1997-04-07 Medarex Inc Bispecifikke reagenser til AIDS-behandling
ATE130850T1 (de) 1989-07-28 1995-12-15 Wako Pure Chem Ind Ltd Fulgimidderivate.
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
ES2193136T3 (es) 1991-08-14 2003-11-01 Genentech Inc Variantes de inmunoglubina para receptores especificos de fc epsilon.
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0625200B1 (en) 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
MX9305070A (es) 1992-08-21 1994-04-29 Genentech Inc Compocicion farmaceutica que contiene un antagonista de lfa-1 para el tratamiento de transtornos o desordenes mediados por el lfa-1
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ATE157455T1 (de) 1993-12-10 1997-09-15 Genentech Inc Methoden zur diagnose von allergie und prüfung anti-allergischer therapeutika
EP0739214B1 (en) 1994-01-18 1998-03-18 Genentech, Inc. A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS
EP0749488A1 (en) 1994-03-03 1996-12-27 Genentech, Inc. Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
DK0877626T3 (da) 1996-01-23 2002-12-30 Univ Vermont Anti-CD18 antistoffer til anvendelse mod slagtilfælde
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
DK1516629T3 (da) 1996-11-27 2013-06-03 Genentech Inc Humaniseret anti-CD-11a antibodies
US20030109680A1 (en) * 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
AU743758B2 (en) 1997-04-07 2002-02-07 Genentech Inc. Anti-VEGF antibodies
ES2293682T5 (es) 1997-05-15 2011-11-17 Genentech, Inc. Anticuerpo anti-apo2.
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
RU2145610C1 (ru) * 1998-12-09 2000-02-20 Общество с ограниченной ответственностью "Протеиновый контур" Способ очистки рекомбинантного эритропоэтина человека
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
ES2329437T3 (es) 1999-06-25 2009-11-26 Genentech, Inc. Anticuerpos anti-erbb2 humanizados y tratamiento con anticuerpos anti-erbb2.
BR0015224A (pt) 1999-10-29 2002-07-09 Genentech Inc Anticorpo anti-antìgeno de célula estaminal prostática (psca) isolado, anticorpo monoclonal anti-psca, ácido nucleico isolado, vetor de expressão, célula, célula hospedeira, método de produção de anticorpo, composição método in vitro para matar uma célula cancerosa que expresse psca, uso de uma anticorpo monoclonal anti-psca e artigo industrializado
AU2003272454A1 (en) * 2002-09-18 2004-04-08 Genencor International, Inc. Protein purification
CN101120017A (zh) * 2004-08-30 2008-02-06 英国龙沙生物医药股份有限公司 用于纯化抗体的亲和力加离子交换层析
EP1693108A1 (en) 2004-12-04 2006-08-23 MERCK PATENT GmbH Mixed-modal anion-exchange type separation material
AU2006259298B2 (en) * 2005-06-17 2012-06-14 Wyeth Llc Methods of purifying Fc region containing proteins
ZA200900836B (en) 2006-08-28 2010-05-26 Ares Trading Sa Process for the purification of FC-fusion proteins
WO2008085988A1 (en) 2007-01-05 2008-07-17 Amgen Inc. Methods of purifying proteins
EP2120915B1 (en) * 2007-01-22 2011-09-28 Genentech, Inc. Polyelectrolyte precipitation and purification of antibodies
CN103833855A (zh) * 2009-06-26 2014-06-04 瑞泽恩制药公司 容易地分离的具有天然免疫球蛋白形式的双特异性抗体
WO2015198451A1 (ja) 2014-06-26 2015-12-30 楽天株式会社 情報処理装置、情報処理方法及び情報処理プログラム

Also Published As

Publication number Publication date
US20220081466A1 (en) 2022-03-17
US20130041139A1 (en) 2013-02-14
KR101764449B1 (ko) 2017-08-02
KR20120106719A (ko) 2012-09-26
BR112012004697B8 (pt) 2021-05-25
US20220324905A1 (en) 2022-10-13
MX2012002565A (es) 2012-05-29
EP2473617A1 (en) 2012-07-11
HRP20200581T1 (hr) 2020-07-10
PL2473617T3 (pl) 2020-06-29
RU2012112536A (ru) 2013-10-10
JP5787891B2 (ja) 2015-09-30
EP3736338A1 (en) 2020-11-11
CN108409829A (zh) 2018-08-17
EP2473617B1 (en) 2020-02-26
BR112012004697B1 (pt) 2021-02-09
US9428548B2 (en) 2016-08-30
RU2571929C2 (ru) 2015-12-27
SI2473617T1 (sl) 2020-07-31
CA2772653C (en) 2019-06-25
JP2013503877A (ja) 2013-02-04
CA2772653A1 (en) 2011-03-10
EP2473617A4 (en) 2014-04-09
ES2787234T3 (es) 2020-10-15
CN102686738A (zh) 2012-09-19
WO2011028753A1 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
BR112012004697A2 (pt) purificação melhorada de proteína através de uma eluição da proteína a modificada.
BR112012024956A2 (pt) processo para a purificação de uma proteína de fator de crescimento
BR112012029904A2 (pt) métodos de purificação de polipeptídeos
BR112013020500A2 (pt) anticorpo isolado, recombinante ou purificado
EA200801531A1 (ru) Способы регулирования содержания маннозы в рекомбинантных белках
WO2013138793A3 (en) Affinity reagants for protein purification
BRPI0709598A8 (pt) composições de polipeptídeos estabilizados
IN2015MN00139A (pt)
AU2018256498A1 (en) Antibodies to amyloid beta
SG159458A1 (en) Novel immunoglobulin-binding proteins with improved specificity
BR112012011305A2 (pt) uso de uma proteína homóloga a uma proteína meab para aumentar a atividade enzimática de uma mutase do ácido 3-hidroxicarboxílico-coa
ECSP13012384A (es) Composición acuosa que contiene bromhexina
BRPI0620125A8 (pt) método para regulação de redução da função biológica de uma proteína, molécula de ocorrência não natural, vetor recombinante, e método para isolar uma protéina de uma amostra
UA115402C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
BR112012014801A8 (pt) uso combinado de proteínas cry1ca e cry1fa para controle de resistência a insetos
WO2010151799A3 (en) Compounds for modulating rna binding proteins and uses therefor
BR112012017124A2 (pt) método de modificação polipeptídica para purificação de multímeros polipeptídicos
BR112014009528A8 (pt) métodos e composições para tratar eritropoiese ineficaz
BR112015023447A2 (pt) purificação de proteínas helicoidais triplas
CO6450656A2 (es) Anticuerpos anti-tnf-alfa y sus usos
MX2009012949A (es) Anticuerpos humanizados que enlazan a ab (1-42) globulomero y usos de los mismos.
MX2013003182A (es) Purificacion de anticuerpos por cromatografia de lecho movil simulada.
UA99262C2 (uk) СПОСІБ ЗМЕНШЕННЯ КОНЦЕНТРАЦІЇ ВІЛЬНИХ Fc-ЧАСТИН В РІДИНІ, ЩО МІСТИТЬ Fc-ВМІСНИЙ БІЛОК
BR112013021562A2 (pt) anticorpos para cd70
CL2012000886A1 (es) Polipeptido que comprende dos secuencias aminoacidas que permiten la union especifica al receptor para productos finales de glicosilacion avanzada (rpfga); uno o mas acidos nucleicos que codifican el polipeptido; celula; composicion; metodo para diagnosticar enfermedad o trastorno con rpfga.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/09/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF